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Abstract
Background: Malignant gastric outlet obstruction (GOO) is commonly seen in patients with
advanced gastric-, pancreatic-, duodenal, hepatobiliary or metastatic malignancies. Ten to 25% of
patients with pancreatic cancer will develop duodenal obstruction during the course of the disease.
Duodenal stenting with self-expandable metal stents is an alternative treatment to surgical bypass
procedures. Our aim was to review the published literature regarding treatment of malignant GOO
with stents to reveal whether the information provided is sufficient to evaluate the clinical effects
of this treatment
Methods:  A literature search from 2000 – 2007 was conducted in Pub Med, Embase, and
Cochrane library, combining the following search terms: duodenal stent, malignant duodenal
obstruction, gastric outlet obstruction, SEMS, and gastroenteroanastomosis.
All publications presenting data with ≥ 15 patients and only articles written in English were included
and a review focusing on the following parameters were conducted: 1) The use of graded scoring
systems evaluating clinical success; 2) Assessment of Quality of life (QoL) before and after
treatment; 3) Information on stent-patency; 4) The use of objective criteria to evaluate the stent
effect.
Results: 41 original papers in English were found; no RCT's. 16 out of 41 studies used some sort
of graded scoring system. No studies had objectively evaluated QoL before or after stent
treatment, using standardized QoL-questionnaires, 32/41 studies reported on stent patency and 9/
41 performed an oral contrast examination after stent placement. Objective quantitative tests of
gastric emptying had not been performed.
Conclusion:  Available reports do not provide sufficient relevant information of the clinical
outcome of duodenal stenting. In future studies, these relevant issues should be addressed to allow
improved evaluation of the effect of stent treatment.
Background
Malignant gastric outlet obstruction (GOO) is commonly
seen in patients with advanced gastric-, pancreatic-, duo-
denal, hepatobiliary or metastatic malignancies. Ten to
25% of patients with pancreatic cancer will develop duo-
denal obstruction during the course of the disease [1,2].
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GOO may result in nausea and vomiting, leading to dehy-
dration and cachexia, which severely reduces the patients'
Quality of Life (QoL).
Traditionally, a surgical by-pass procedure, usually a gas-
trojejunoanastomosis (GEA), has been the palliative treat-
ment offered, but up to 31% of the patients do not
experience sufficient symptom relief following GEA [1,3].
Furthermore, GEA has a peri-operative morbidity as high
as 35% and a mortality rate of about 2% in later studies
[1,4-7].
Duodenal stenting with self-expandable metal stents
(SEMS) is an alternative treatment to surgical bypass pro-
cedures. In several studies, this treatment has been evalu-
ated as safe and efficient with a technical success rate of
90–100%, a clinical success rate of 67–100%, a rate of
severe complications about 7% and non-severe complica-
tion rate about 20% [2,6-8,8-47]. Compared with surgery,
the patients treated with stents have fewer serious compli-
cations and less need for intensive care unit (ICU) [5] Fur-
thermore, the hospital stay is shorter, which is essential in
palliative treatment [5,9,20,32,7].
In palliative cancer treatment, improvement of QoL is a
primary goal and needs to be addressed when new treat-
ment strategies and procedures are implemented and eval-
uated. Relief from obstructive symptoms is the most
important parameter for evaluating the clinical effect or
treatment outcome following duodenal stenting of GOO,
but complications, stent patency and need for re-interven-
tions are also parameters influencing QoL. In the availa-
ble reports, objective criteria of treatment effects are often
missing, which make it difficult to compare results and
draw conclusions concerning effects of the treatment
offered.
To review the published literature regarding treatment of
malignant GOO with stents to reveal whether the infor-
mation provided is sufficient to evaluate the clinical
effects of this treatment, and whether QoL has been
assessed.
Methods
A search for published literature for the time period Janu-
ary 2000 – September 2007 was conducted in Pub Med,
Embase, and Cochrane library, combining the following
search terms: duodenal stent, malignant duodenal
obstruction, gastric outlet obstruction, SEMS, and gastro-
enteroanastomosis. Reference lists were hand-searched
for additional literature. Furthermore, reference lists of
review articles and metaanalyses from the relevant time
period were used to identify additional literature.
Abstracts were not included. Only studies presenting data
with ≥ 15 patients and only articles written in English
were included in the present review. When studies
included identical patients, the most recent study was
included.(see additional file 1)
The identified studies were reviewed with regard to the
following parameters:
1. The use of a graded scoring systems evaluating clinical
success
2. Assessment of QoL before and after treatment
3. Information on stent-patency
Stent patency defined as the time period without need for
re-intervention
4. The use of objective criteria to evaluate the stent effect
Results
When applying the search criteria, 41 original papers and
four review articles in English were found (See table 1).
The number of patients included in the original papers
was 15–213. Of the studies using a combined endoscopic/
fluoroscopic method for stent placement ten were pro-
spective and 18 retrospective, corresponding numbers for
the studies in which only fluoroscopy was applied were 10
and three, respectively. All prospective and retrospective
studies are listed in table 2 and 3 respectively. No rand-
omized controlled trials (RTC's) treating ≥ 15 patients
with stents were found.
Clinical effect and scoring systems
To evaluate the clinical effects of stent treatment, 16 out of
41 studies used some sort of graded scoring system (see
table 4). The level of oral intake before and after stent
treatment was divided into four to five levels, which
Table 1: Characteristics of studies included in the review (n = 41)
Characteristics n (% of total)
Prospective studies 20 (49%)
Retrospective studies 21 (51%)
Stent deployed by fluoroscopic guidance 13 (32%)
Stent deployed by combined endoscopic/fluoroscopic guidance 28 (68%)BMC Gastroenterology 2009, 9:45 http://www.biomedcentral.com/1471-230X/9/45
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allows some comparison of the results. The scoring sys-
tems used are adapted from studies on dysphagia in
esophageal cancer. One of the most frequently used is
Gastric Outlet Obstruction Scoring System (GOOSS) pre-
sented by Adler in 2002 [2] (0 = no/inadequate oral
intake, 1 = liquids/thickened liquids, 2 = semisolids/low
residue diet, 3 = unmodified diet). This system assigns a
point score based on the level of oral intake. Song et al
[48] introduced another similar scoring system (0 = able
to eat normal diet, 1 = able to tolerate fragmented solid
food without vomiting, 2 = able to tolerate soft food with-
out vomiting, 3 = able to tolerate only liquid diet without
vomiting, 4 = not able to tolerate any oral intake without
vomiting, 5 = vomiting even without oral intake), mostly
used in radiological literature, in which vomiting as an
important symptom of obstruction is included. The
GOOSS score was applied by 6/41 studies, 1/41 applied
the Song score and 8/41 used similar graded scores. Fur-
thermore, in 2007 Lowe et al introduced a Gut function
score (0 = profuse vomiting or gut not functioning, 1 =
nausea and occasional vomiting, 2 = nausea only, 3 = nor-
mal gut function). This function score is used in addition
to GOOSS and grades the level of nausea and vomiting. At
present, the Gut Function Score has only been applied in
the study, in which it was originally presented [44].
QoL in the evaluation of clinical success
No studies had objectively evaluated QoL before or after
stent treatment, using standardized QoL-forms (see table
4). Seven of 41 studies used the Karnofsky performance
scale before and after stent treatment (A physical perform-
ance scale from 100-0, where a scoring of 100 is normal
function and 0 is dead).
Stent patency
Concerning stent patency, 32/41 studies reported on this
variable (see table 4), either by reporting the exact number
of stent failures and time to failure after stent deployment
or by calculating the patency. The rate of re-obstruction
was reported in 36/41 studies, the migration rate in 34/41
studies.
Objective criteria for stent function
An oral contrast examination was performed after stent
placement in 9/41 studies (see table 4). Objective quanti-
tative tests of gastric emptying before and after treatment
were not performed in any of the evaluated studies.
Discussion
The present review demonstrates that a graded scoring sys-
tem for symptom assessment was used in 40% of the eval-
uated papers. No studies provided information on QoL,
although 17% of the studies used the Karnofsky scale.
Table 2: Prospective studies
Author Year Patients (n)
Jung (16) 2000 19
Lopera (11) 2001 16
Pabon (12) 2001 29
J.H. Kim (13) 2001 29
Park (14) 2001 24
Jung (17) 2002 39
Lee(21) 2003 17
Tang (22) 2003 21
Nassif (23) 2003 63
Holt (26) 2004 28
Jeong (27) 2004 25
Johnsson (5) 2004 21
Hayashi (47) 2005 31
Yoon (35) 2006 82
Espinel (36) 2006 24
Song (42) 2007 20
Mutignani(43) 2007 64
J.H Kim (41) 2007 213
Lowe(44) 2007 87
Maetani (45) 2007 37
Table 3: Retrospective studies
Author Year Patients (n)
Yim (9) 2001 29
Razzaq (10) 2001 23
Aviv (18) 2002 15
Maetani (15) 2002 23
Adler (2) 2002 36
M. Kaw (19) 2003 18
Mittal (6) 2003 16
Stawawy (20) 2003 24
G.H. Kim (24) 2004 49
Lindsay (25) 2004 40
Telford (29) 2004 176
Mosler (30) 2005 36
Bessoud (32) 2005 72
Del Piano (31) 2005 24
Maetani (7) 2005 22
Maire (33) 2006 24
Kazi (34) 2006 23
Kiely (37) 2007 30
T.O. Kim (40) 2007 53
J. van Hooft (38) 2007 62
Jeurnink (8) 2007 53
Table 4: Evaluation criteria applied in the reviewed studies 
(n = 41)
Evaluation criteria n (% of total)
Quality of Life assessment 0
Objective criteria for stent function 9 (22%)
Clinical effect by graded scoring 15 (37%)
Stent patency 33 (80%)BMC Gastroenterology 2009, 9:45 http://www.biomedcentral.com/1471-230X/9/45
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Information on stent patency was given in 80% of the
studies and 22% had performed oral contrast examina-
tion following stent placement to objectify the stent effect.
No studies quantified the effect of stent placement on rate
of gastric emptying.
The main complaints of patients suffering from malignant
duodenal obstruction are often nausea, severe vomiting,
bloating and abdominal pain. It is questionable whether
the applied scoring systems in the papers reviewed pro-
vide adequate and sufficient information about relief
from these symptoms after stent placement. Improvement
of symptoms estimated by a dysphagia score provides lim-
ited information concerning the effect of duodenal stent-
ing, and should thus be used in combination with a
scoring system providing information about the more
characteristic symptoms of GOO. The Gut Function Score
may be a step in the right direction [44], but this scoring
system needs further evaluation and validation.
In the present review, no studies were identified using
standardized forms to assess QoL before and after stent
treatment. One randomized study used SF-36 to evaluate
the QoL in 10 patients treated with duodenal stents [49],
which is a validated and frequently used QoL question-
naire. This study was, however, too small for inclusion in
this review. In 16% of the studies, the Karnofsky scale was
used, but this scale captures only one aspect of QoL (phys-
ical function) and is today considered inadequate for eval-
uation of QoL [51]. Also for surgical treatment of GOO,
data on the effect of QoL is limited [3]. There have been
developed and validated several complex and advanced
questionnaires for specific symptoms and specific diseases
for the assessment of QoL [51]. EORTC C30 and the organ
specific modules are now widely used for the evaluation
of palliative cancer treatment. By applying these validated
tools, the information about the QoL of patients is
improved, and a possible discrepancy between the QoL of
the patient estimated by the physician and the patient
might be revealed. Studies regarding QoL in palliative
cancer treatment have shown that physicians tend to over-
estimate improvement in QoL of the patients [52,53].
Stent-patency related to survival is an important parameter,
because the need for re-interventions and re-hospitaliza-
tions most likely will reduce the patients QoL. Re-obstruc-
tion of the stent by tumor in- and overgrowth is known to
occur in 15–20% of the patients [28] and is probably the
most important factor influencing stent patency.
The main effect of stent treatment in GOO is re-establish-
ing the passage of food from the stomach to the duode-
num. Evaluation of the stent effect can hence be provided
by measuring the rate of gastric empting before and after
stent placement. None of the reviewed studies included
information on this issue. In a recent study by Maetani et
al, delayed gastric emptying of a liquid meal after stent
placement was demonstrated. The patients resumed oral
intake after stenting and those with a severe delay of emp-
tying had a reduced survival time [54]. Rate of gastric
emptying was, however, only recorded after stenting, and
the quantitative effect of stenting was thus not revealed.
More detailed data on the effect of stenting on rate of gas-
tric emptying is thus required, and can be used to improve
the knowledge on the relation between GOO and obstruc-
tive symptoms. This is an important issue, since the rela-
tion between gastrointestinal symptoms and gastric
emptying might be rather weak [55]. Furthermore, knowl-
edge concerning the effect of SEMS on gastric emptying
could possibly help identifying subgroups of patients, in
which stenting is particularly beneficial. Gastric emptying
is a complex process involving grinding and emptying of
the meal, and it is not likely that the re-establishment of
passage is followed by a more rapid rate of gastric empty-
ing in all subjects treated.
Conclusion
Only 40% of the studies reviewed used a graded scoring
system to evaluate the clinical effect of their treatment.
Furthermore, most studies using a graded scoring system
applied a point score adapted from dysphagia in esopha-
geal cancer and did thereby not address the symptoms
more specific for GOO. The presence of obstructive symp-
toms (severe vomiting, nausea and bloating) is probably
severely reducing the patients QoL. In palliative cancer
care, improvement of QoL is a main treatment goal, and
data on this issue are missing in all the evaluated papers.
Objective evaluation of gastric/duodenal function after
stenting is limited and no studies have performed quanti-
tative tests of gastric emptying. The present review thus
indicates that the available reports do not provide suffi-
cient relevant information of the clinical outcome of duo-
denal stenting. In future studies, these relevant issues
should be addressed to allow improved evaluation of the
effect of stent treatment.
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